ACC 2023: Large bore mechanical thrombectomy reduces adverse outcomes in high-risk PE patients

LARGE BORE MECHANICAL thrombectomy with the FlowTriever system in patients with high-risk pulmonary embolism (PE) was associated with a significantly lower occurrence of meaningful in-hospital adverse clinical outcomes compared to other contemporary treatments, data presented at the American College of Cardiology (ACC) 2023 Scientific Sessions (March 4–6) in New Orleans indicate.

These were among the results of the FLAME study, a prospective, non-randomised study of interventional treatment in high-risk PE, a patient population with a historical mortality rate of 25-50%, which were presented at ACC 2023 by Mitchell Silver, MD, from OhioHealth Heart and Vascular in Mansfield, Ohio.

The study collected data on patients treated with the FlowTriever and on those treated with other therapies in a context arm. The primary endpoint measured a composite of meaningful in-hospital clinical outcomes, including mortality, major bleeding, clinical deterioration, and escalation to an alternate therapy.

Silver reported that FLAME was stopped early after meeting the pre-specified interim analysis criterion at 50 FlowTriever